Speak with Chinese data! Tianjin IBD Diagnosis and Treatment Quality Control Center speaks out

For medical professionals only

How to explore the experience of using IBD biologics in line with China's national conditions? Listen to the interview with Professor Cao Hailong, Department of Gastroenterology, General Hospital of Tianjin Medical University!

First, "IBD diagnosis and treatment quality control evaluation center (IBDQCC)" aims to promote China's IBD grading diagnosis and treatment and improve the level of quality control management of IBD standardized diagnosis and treatment, Tianjin Medical University General Hospital is the first approved national IBD regional diagnosis and treatment center in Tianjin, can you please introduce what help the center construction provides to IBD patients and clinical research?

★ Professor Cao Hailong

Expert of the gastroenterology team of the General Hospital of Tianjin Medical University

2.

★ Professor Cao Hailong

At present, the treatment of IBD has entered the era of

How was this study designed for patient recruitment, medication, and clinical endpoints? What kind of challenges and difficulties were encountered in the research process? How was it overcome? What are the feelings and ideas I would most like to talk about about the entire study, including the abstract release at the AOCC meeting?

★ Professor Cao Hailong

Fourth, IBD condition is complex, diagnosis is difficult, the need to regularly monitor the progress of the disease and long-term disease management, but also need the close cooperation of patients and doctors, please share from the patient self-management, hospital diagnosis and treatment and other aspects of how to develop IBD disease management strategy?

★ Professor Cao Hailong

IBD patient management is very important for IBD specialists, clinically, it is often seen that the diagnosis of the disease is delayed due to the lack of attention to the disease, the irregular use of drugs, the lack of timely review, etc.
, and the best treatment time is missed
.

After the establishment of the IBD Center of our hospital, the IBD expert team and professional nursing team have been established, which has improved the level of standardized diagnosis and treatment and quality control management, optimized the diagnosis and treatment process, and saved economy and time cost
for patients.

In terms of patient management, adopt a one-to-one management strategy and establish WeChat groups and email groups for patients; For patients who cannot come to the hospital for medical treatment, IBD diagnosis and treatment is carried out using the shortcut of online diagnosis and drug delivery to home, which greatly improves patient compliance and thus improves clinical efficacy
.

ask

V.
In the process of using biologics to treat IBD, is it necessary to develop an individualized plan? What experience can I share in the individualized treatment of IBD using vidlizumab?

★ Professor Cao Hailong

The choice of personalized biologics is a clinical challenge involving issues such as doctor-patient co-decision-making, and IBD specialists need to play a key role
.

The development of an individualized regimen requires a comprehensive assessment of the patient's age, extent of lesions, and the presence of other comorbidities (e.
g.
, fistula), opportunistic infections, anemia, or upper gastrointestinal involvement, before selecting biologics
based on the assessment.

In terms of drug efficacy, vederizumab is currently the only intestinal selective biologic in the field of IBD, which has a good effect in general UC and CD patients, and for patients with combined extraintestinal manifestations (such as joint symptoms), fistula, upper gastrointestinal involvement, opportunistic infection or severe disease, it is necessary to consider whether to combine hormones or use systemic biologics for further treatment; In terms of safety, vidlizumab is at the top
of the biologic "safety pyramid".

In terms of accessibility, as a biologic agent that enters China's class B medical insurance, viderizumab can reduce the medical economic cost of patients, so it can be accepted
by more patients.
Although we still need to rely on experience in the use of biologics, this problem has attracted the attention of scholars around the world, and our IBD center has also established a relevant database, hoping to sort out more valuable data
.

I look forward to more clinical studies, AI simulations, or big data analytics that will help us find the patterns by which biologics treat patients with different IBDs, thereby solving the clinical challenge of biologics selection and adding more confidence
to patients and physicians.
"
Expert Profiles

Professor Cao Hailong

• Deputy Director and Chief Physician of the Department of Gastroenterology, General Hospital of Tianjin Medical University, Deputy Director of Tianjin Institute of Digestive Diseases

• Doctor of Medicine, Postdoctoral Fellow in Pharmacy, Doctoral Supervisor

• Youth Member of inflammatory Enterology Group of Digestive Disease Branch of Chinese Medical Association

• Member of the Gastrointestinal Tumor Collaboration Group of the Digestive Disease Branch of the Chinese Medical Association

• Deputy Leader of the Early Cancer Group of the Digestive Disease Branch of Tianjin Medical Association

• Tianjin 131 innovative talents, Tianjin colleges and universities backbone innovation talents, Tianjin health industry high-level talents

• He is a communication review expert of the National Natural Science Foundation of China, presided over the completion of more than ten key projects of the National Natural Science Foundation of China and the Tianjin Municipal Science and Technology Commission, won the DDW Conference Young Scholar Research Award in the United States, and published more than 100 papers in Gut and other journals

References:

[1] Kaplan GG.
The global buden of IBD: from 2015 to 2025[J].
NatRev Gastroenterol Hepatol, 2015 , 12 ( 12) :720-727.
[2] Cao HL, et al.
Short-term effectiveness and safety of vedolizumab in patients with inflammatory bowel disease: a single-center retrospective study in China.
2022 AOCC Abstract P228.

Approval number: VV-MEDMAT-73579

Approval date: September 2022

Disclaimer: This information is intended to help healthcare professionals better understand the latest developments
in related disease areas.

The content of the information published by this platform does not mean that it agrees with its description and views, and only provides more information
.

If copyright issues are involved, please contact us and we will deal with
them as soon as possible.

The information provided in this information is not in any way a substitute for professional medical guidance and should not be construed as a medical recommendation
.

If such information is used for a purpose other than to understand the information, the Platform, the author and Takeda shall not be liable
.

- End -

This article is only used to provide scientific information to medical professionals and does not represent the position of the Platform